ArticleBMC cancer2023
Survival outcomes of esophageal cancer patients with recurrence after curative treatments.
Article in BMC cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.
- Neutrophil-to-lymphocyte ratio in unresectable or metastatic esophageal squamous cell carcinoma: a systematic review, meta-analysis and meta-regression.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Pooled it
- Pooled it
- Long-term outcome of PDT for local failure after CRT or RT for oesophageal cancer.Journal of gastroenterology · 2026Trial
- Prognostic Value of Circulating Exosomal DNA in Esophageal Squamous Cell Carcinoma: A Prospective Cohort Study.Annals of surgical oncology · 2026Article
- Outcomes of transmediastinal esophagectomy for patients with esophagogastric junction cancers.International journal of clinical oncology · 2026Article
- Recurrence After Esophagectomy for Esophageal Cancer: High-Volume Center Surveillance Imaging Outcomes.Annals of surgical oncology · 2026Article
- Observational
- Mastering esophageal cancer imaging: what radiologists need to know.Abdominal radiology (New York) · 2025Review
- A pilot study of tegafur-uracil maintenance on survival in patients with esophageal squamous cell carcinoma following definitive chemoradiotherapy.Scientific reports · 2025Article
- Organ Preservation in Esophageal Cancer: Current Strategies, Challenges, and Future Directions.Cancers · 2025Review
- Survival Outcomes of Esophageal Squamous Cell Carcinoma Patients Who Underwent Salvage Esophagectomy: A Literature Review and Results From Two High-Volume Centers.Annals of gastroenterological surgery · 2025Article
- Salvage Chemoradiotherapy for Loco-Regional Recurrence of Esophageal Squamous Cell Carcinoma After Esophagectomy.Journal of clinical medicine · 2025Article
- Real-world clinical characteristics and outcomes of patients with locally advanced, unresectable esophageal/gastroesophageal junction cancer treated with definitive chemoradiotherapy in the United States community oncology setting.Frontiers in oncology · 2025Article
- Machine learning and the nomogram as the accurate tools for predicting postoperative malnutrition risk in esophageal cancer patients.Frontiers in nutrition · 2025Article
- Proximal Margin Involvement Following Total Gastrectomy for Seiwert III Adenocarcinoma: A Management Dilemma.Cureus · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLittle is known about predictive factors for survival outcomes of esophageal carcinoma (EC) patients who developed recurrence after undergoing multimodal therapies. We aimed to investigate long-term outcomes and identify prognostic factors in patients with relapsed EC, focusing especially on those with oligometastasis (OM).
methodsEC patients who developed recurrence after curative treatments (radical esophagectomy or definitive chemoradiotherapy (dCRT)) between 2010 and 2017 were reviewed. Multivariate Cox hazards models were applied to determine independent predictors of poor post-recurrence survival (PRS).
resultsIn total, 178 patients were included. The median PRS was 12.9 months. Of the 178 patients, 98 had OM and 80 non-OM (NOM) disease. The survival outcomes of patients with OM were significantly better than those of patients with NOM (P < 0.01). Surgical treatments provided significantly better survival outcomes than CRT or chemo-/radiotherapy alone (3-year overall survival (OS); 78.1% vs. 42.5% vs. 28.9%, P < 0.01), mainly due to prolonging survival after the recurrence (3-year PRS 62.9% vs. 16.7% vs. 16.2%, P < 0.01). Multivariable analysis focusing on patients with OM revealed cStage III-IV disease (P < 0.01), high GPS at the time of recurrence (P = 0.02) and non-curative treatments (P < 0.01), to be independently associated with poor PRS. In contrast, in patients with NOM, no independent predictors for poor PRS were identified.
conclusionsThe survival outcomes of patients with relapsed EC remain poor. Surgical treatments could provide survival benefits for patients with recurrent EC, especially for patients with OM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.